Aligos rises as FDA clears application to begin trials for NASH drug

Aligos Therapeutics

21/09/2023 13:16

** Shares of Aligos Therapeutics Inc  ALGS.O  rise 8.85% to
about 86 cents premarket
    ** Co says it has received clearance of its application from
the US FDA to start trials for ALG-055009 in humans, which is
intended for the treatment of a liver disease known as
nonalcoholic steatohepatitis (NASH)
    ** Co remains on track to submit mid-stage study protocol in
Q4 2023 and expects to initiate enrollment in Q1 2024
     ** ALGS looks forward to share top-line proof of concept
data from the study in Q4 2024
    ** NASH is a fatty liver disease where fat accumulation and
inflammation can lead to scarring, or fibrosis, that impairs
liver function
    ** Up to last close, stock down ~17% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))